Early (2 weeks) vs. late (8 weeks) initiation of highly active antiretroviral treatment (HAART) significantly enhance survival of severely immunosuppressed HIV-infected adults with newly diagnosed tuberculosis: results of the CAMELIA clinical trial

類似資料

• Causes and Determinants of Mortality in HIV-Infected Adults With Tuberculosis: An Analysis From the CAMELIA ANRS 1295-CIPRA KH001 Randomized Trial
  著者:: Marcy, Olivier, 等
  出版事項: (2014)
• Earlier versus Later Start of Antiretroviral Therapy in HIV-Infected Adults with Tuberculosis
  著者:: Blanc, François-Xavier, 等
  出版事項: (2011)
• Plasma Concentrations, Efficacy and Safety of Efavirenz in HIV-Infected Adults Treated for Tuberculosis in Cambodia (ANRS 1295-CIPRA KH001 CAMELIA Trial)
  著者:: Borand, Laurence, 等
  出版事項: (2014)
• TB-IRIS and remodelling of the T cell compartment in highly immunosuppressed HIV+ patients with TB: the CAPRI T (ANRS-12614) study
  著者:: Haridas, V., 等
  出版事項: (2015)
• A set of plasmatic microRNA related to innate immune response highly predicts the onset of immune reconstitution inflammatory syndrome in tuberculosis co-infected HIV individuals (ANRS-12358 study)
  著者:: Polidy Pean, 等
  出版事項: (2025-06-01)